Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis

Abstract

One suitable approach to enhancing multiple sclerosis (MS) treatment is combination of available medications to provide more desirable outcomes. Immunomodulatory effects of atorvastatin and/or all-trans retinoic acid (ATRA) were determined in previous studies. The present study was set out to investigate the synergistic effects of combination therapy by suboptimal doses of atorvastatin and ATRA in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. EAE was induced by MOG35-55 in female C57BL/6 mice. Therapies were initiated at day 12 post immunization when the mice developed a disability score and continued throughout the study until the day 33 when animals were sacrificed. Therapeutic treatment with half doses of atorvastatin and ATRA in combination has synergistic benefits causing the regression of clinical and neuropathological features of EAE more favorable than treatment with full doses of either drug alone. Without any advantage in anti-proliferative effect, combination treatment significantly reduced the secretion of pro-inflammatory cytokine interleukin-17 and conversely, increased the production of anti-inflammatory cytokine interleukin-10 more prominent than either drug alone. Furthermore, FoxP3+Treg cells were significantly increased only in combination treatment. In conclusion, combined atorvastatin and ATRA have immunomodulatory synergistic benefits and this pharmacological approach may be as a useful strategy to control MS.

RETRACTED ARTICLE: Preconditioning with pitavastatin, an HMG-CoA reductase inhibitor, attenuates C-Jun N-terminal kinase activation in experimental subarachnoid hemorrhage-induced apoptosis

“…It is now considered more effective at improving cardiovascular function compared to its primary cholesterol-lowering effects. Owing to statins havig a number of cholesterol-independent pleiotropic actions including increasing NO bioavailability and reduction of oxidative damage in both in vitro and in vivo studies, statins show promise in reducing the risk of cerebral ischemia, coronary artery disease and multiple sclerosis [1,14]. In Wolozin et al's study, statins were reported to mediate the apolipoprotein E4 variant, which imposes a risk of Alzheimer's disease [45].…”

“…Pitavastatin, a 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA) inhibitor, has been used in the treatment of dyslipidemia and prevents intracellular cholesterol synthesis [1,8,9,14,45]. It is now considered more effective at improving cardiovascular function compared to its primary cholesterol-lowering effects.…”

The future of multiple sclerosis treatments

“…We and others showed that re-purposing molecules such as angiotensin converting enzyme inhibitors or retinoids can be effective in the animal model of MS or promote remyelination [141,[174][175][176]. It is probable that repurposing drug development will play a bigger role in the future despite the inherent pitfalls which impact its feasibility [177].…”

Caffeine alters the effects of bone marrow-derived mesenchymal stem cells on neutrophils

“…18,19 Briefly, 100 µL of the neutrophil suspension (2 × 10 6 cells/ml) was added to each well of 96-well microplates and pulsed with 20 μL of the MTT solution (5 mg/mL) for 4 h at 37°C. To dissolve the formazan crystals, 150 µL DMSO was added to each well of 96-well microplates and the plates were shaken vigorously.…”